Antibody-drug conjugates (ADCs) are currently considered to be promising agents for cancer therapy. However, especially in solid tumors, the uneven distribution of ADCs would decrease their efficacy in clinical studies. We suggest that in addition to optimizing ADC components, such as the linker structure and anticancer agent, it is necessary to consider the distribution of the ADC within tumor tissue. In this study, we established three kinds of anti-tissue factor (TF) ADCs: 1849ADC with a low kd, 444ADC with an intermediate kd, and 1084ADC with a high kd. All three of the anti-TF ADCs exhibited almost the same in vitro cytotoxicity and pharmacological and biochemical characteristics, although the binding kinetics parameters differed. In vivo, all ADCs exerted equivalent antitumor effects against small BxPC3 tumors. However, on larger BxPC3 tumors, 1084ADC (higher kd) exerted higher antitumor activity than 1849ADC (lower kd). Furthermore, immunofluorescence staining indicated that 1084ADC was distributed throughout the whole tumor, whereas 1849ADC was mainly localized close to tumor vessels. We conclude that the ADC with a higher kd increased the antitumor effect of because it penetrated and distributed evenly throughout the entire solid tumor. These findings highlight the importance of the kd of a mAb in ADC design.
Bispecific antibodies are biotherapeutics that amalgamate the specificities of two distinct antibodies into one molecule. Bispecific antibodies can be utilized in a broad range of diagnostic and therapeutic applications; however, their engineering requires genetic modification and remains time-consuming. Therefore, in this study, we used AJICAP second-generation technology, which drives the production of site-specific antibody-drug conjugates in a practical and robust manner, without genetic modification requirements, to generate bispecific antibodies. Using haloketone chemistry as an alternative to maleimide chemistry, which carries reaction risks, we successfully produced site-specific antibody conjugates. Pharmacokinetic studies revealed that the haloketone-based antibody conjugate was stable in the rat plasma. The resultant bispecific antibodies were rigorously evaluated, and surface plasmon resonance measurements and flow cytometry analyses confirmed that antigen binding remained intact. Additionally, the affinity for the neonatal Fc receptor (FcRn) was retained after conjugation. Further cytotoxicity evaluation emphasized the pronounced activity of the generated bi-specific antibodies. These preliminary findings highlight the potential of AJICAP second-generation technology in BisAb production. This novel approach introduces a fully chemical, site-specific strategy capable of producing bispecific antibodies, heralding a new era in the field of biotherapeutics.